Pliant Therapeutics Statistics
Total Valuation
PLRX has a market cap or net worth of $106.82 million. The enterprise value is -$95.68 million.
Important Dates
The next estimated earnings date is Friday, November 7, 2025, after market close.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PLRX has 61.39 million shares outstanding. The number of shares has increased by 1.67% in one year.
| Current Share Class | 61.39M |
| Shares Outstanding | 61.39M |
| Shares Change (YoY) | +1.67% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 77.69% |
| Float | 51.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.49 |
| P/TBV Ratio | 0.49 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.99, with a Debt / Equity ratio of 0.27.
| Current Ratio | 12.99 |
| Quick Ratio | 12.84 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -66.24 |
Financial Efficiency
Return on equity (ROE) is -67.55% and return on invested capital (ROIC) is -37.47%.
| Return on Equity (ROE) | -67.55% |
| Return on Assets (ROA) | -35.07% |
| Return on Invested Capital (ROIC) | -37.47% |
| Return on Capital Employed (ROCE) | -78.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 171 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.29% in the last 52 weeks. The beta is 1.41, so PLRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -88.29% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 2.47 |
| Relative Strength Index (RSI) | 57.08 |
| Average Volume (20 Days) | 1,036,804 |
Short Selling Information
The latest short interest is 3.83 million, so 6.24% of the outstanding shares have been sold short.
| Short Interest | 3.83M |
| Short Previous Month | 3.75M |
| Short % of Shares Out | 6.24% |
| Short % of Float | 7.39% |
| Short Ratio (days to cover) | 6.66 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -219.86M |
| Pretax Income | -206.96M |
| Net Income | -206.96M |
| EBITDA | -217.98M |
| EBIT | -219.86M |
| Earnings Per Share (EPS) | -$3.39 |
Full Income Statement Balance Sheet
The company has $262.87 million in cash and $60.38 million in debt, giving a net cash position of $202.50 million or $3.30 per share.
| Cash & Cash Equivalents | 262.87M |
| Total Debt | 60.38M |
| Net Cash | 202.50M |
| Net Cash Per Share | $3.30 |
| Equity (Book Value) | 220.08M |
| Book Value Per Share | 3.59 |
| Working Capital | 246.85M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$169.40 million and capital expenditures -$1.48 million, giving a free cash flow of -$170.88 million.
| Operating Cash Flow | -169.40M |
| Capital Expenditures | -1.48M |
| Free Cash Flow | -170.88M |
| FCF Per Share | -$2.78 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.67% |
| Shareholder Yield | -1.67% |
| Earnings Yield | -193.76% |
| FCF Yield | -159.98% |
Analyst Forecast
The average price target for PLRX is $3.93, which is 125.86% higher than the current price. The consensus rating is "Hold".
| Price Target | $3.93 |
| Price Target Difference | 125.86% |
| Analyst Consensus | Hold |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -9.61% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |